The U.S. Food and Drug Administration (FDA) revised the boxed warning on the label for Metformin Hydrochloride, effective 2026-06-19. The update details postmarketing cases of metformin-associated lactic acidosis, which have resulted in severe outcomes including death, hypothermia, hypotension, and resistant bradyarrhythmias. This revision emphasizes the subtle onset of this serious adverse event.
Background
Metformin Hydrochloride is a medication that appears both as a standalone therapy and in combination products, such as canagliflozin and metformin hydrochloride. Its therapeutic context often involves other agents like dapagliflozin and empagliflozin. The risk of lactic acidosis has historically been associated with metformin-containing products, leading to the establishment of a boxed warning to highlight this serious potential adverse effect.
What this means
The FDA's revision of the boxed warning for Metformin Hydrochloride serves as a critical update for all prescribing clinicians and pharmacists. The explicit mention of specific severe outcomes from postmarketing cases—including death, hypothermia, hypotension, and resistant bradyarrhythmias—reinforces the life-threatening potential of metformin-associated lactic acidosis. The emphasis on the subtle onset of this condition is particularly important, as it suggests that initial symptoms may be non-specific or easily overlooked, potentially delaying diagnosis and intervention. Healthcare providers should maintain a high index of suspicion for lactic acidosis in patients receiving Metformin Hydrochloride, especially those with predisposing risk factors. Prompt recognition of symptoms such as malaise, myalgia, respiratory distress, and abdominal pain, even in the absence of overt signs of acidosis, is crucial. This updated warning necessitates a renewed focus on patient education regarding potential symptoms and when to seek immediate medical attention, as well as careful monitoring of renal function and other relevant clinical parameters in patients on Metformin Hydrochloride therapy.
Source
The U.S. Food and Drug Administration (FDA) announced this label revision on 2026-06-19. The full details are available on the DailyMed website, hosted by dailymed.nlm.nih.gov, under the specified set ID.